Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive interim analysis results from a Phase III clinical study for its anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) benmelstobart (TQB2450) in combination with anlotinib for the treatment of advanced unresectable or metastatic renal cell carcinoma (RCC). The primary endpoint of the study, progression-free survival (PFS), successfully met the optimal efficacy threshold outlined by the study protocol. Additionally, the secondary endpoint, overall survival (OS), indicated a trend of benefit.
Benmelstobart received marketing approval in China earlier this month for the treatment of first-line extensive stage small cell lung cancer (ES-SCLC) in combination with anlotinib and chemotherapy. Anlotinib, an oral multi-target kinase inhibitor, obtained marketing approval for the treatment of previously treated advanced non-small cell lung cancer (NSCLC) in China in May 2018. Since then, it has received additional indications for soft tissue sarcoma, SCLC, medullary thyroid carcinoma, differentiated thyroid carcinoma, and ES-SCLC.- Flcube.com
